The global AI-Enabled Radioligand Therapy (Theranostics) market was valued at $1.8 billion in 2025 and is projected to reach $14.2 billion by 2034, expanding at a robust compound annual growth rate (CAGR) of 29.5% during the forecast period 2026-2034, driven by converging advances in artificial intelligence, radiopharmaceutical sciences, and precision oncology.

https://researchintelo.com/rep....ort/ai-enabled-radio